Evidence map›Paper›PMID 25243408›Full record

ArticlePloS one2014

Quantification of the heterogeneity of prognostic cellular biomarkers in ewing sarcoma using automated image and random survival forest analysis.

Claudia Bühnemann, Simon Li, Haiyue Yu, Harriet Branford White, Karl L Schäfer, Antonio Llombart-Bosch, Isidro Machado, Piero Picci, Pancras C W Hogendoorn, Nicholas A Athanasou and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Targeting the EphA2 pathway: could it be the way for bone sarcomas?Cell communication and signaling : CCS · 2024
    Review
  2. Article
  3. Article
  4. Review
  5. Role of immunotherapy in Ewing sarcoma.Journal for immunotherapy of cancer · 2020
    Review
  6. Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis.International journal of computer assisted radiology and surgery · 2020
    Review
  7. Article
  8. Review
  9. Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 5 countries.

Claudia BühnemannCR-UK, Tumour Growth Group, Oxford Molecular Pathology Institute, Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Simon LiInstitute of Biomedical Engineering, Department of Engineering Science, Old Road Campus Research Building, University of Oxford, Headington, Oxford, United Kingdom.
Haiyue YuCR-UK, Tumour Growth Group, Oxford Molecular Pathology Institute, Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom; Institute of Biomedical Engineering, Department of Engineering Science, Old Road Campus Research Building, University of Oxford, Headington, Oxford, United Kingdom.
Harriet Branford WhiteCR-UK, Tumour Growth Group, Oxford Molecular Pathology Institute, Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Karl L SchäferInstitute of Pathology, Heinrich-Heine University, Medical Faculty, Düsseldorf, Germany.
Antonio Llombart-BoschPathology Department, University of Valencia, Valencia, Spain.
Isidro MachadoPathology Department, University of Valencia, Valencia, Spain.
Piero PicciResearch, The Rizzoli Institute, Bologna, Italy.
Pancras C W HogendoornDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Nicholas A AthanasouNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford, Oxford, United Kingdom.
J Alison NobleInstitute of Biomedical Engineering, Department of Engineering Science, Old Road Campus Research Building, University of Oxford, Headington, Oxford, United Kingdom.
A Bassim HassanCR-UK, Tumour Growth Group, Oxford Molecular Pathology Institute, Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
University of Oxford · GBInstitute of Biomedical Science · GBOxford Research Group · GBUniversitat de València · ESHeinrich Heine University Düsseldorf · DEIstituto Ortopedico Rizzoli · ITLeiden University Medical Center · NL

Funding

Cancer Research UK 9891
6 · The paper itself

Abstract

Driven by genomic somatic variation, tumour tissues are typically heterogeneous, yet unbiased quantitative methods are rarely used to analyse heterogeneity at the protein level. Motivated by this problem, we developed automated image segmentation of images of multiple biomarkers in Ewing sarcoma to generate distributions of biomarkers between and within tumour cells. We further integrate high dimensional data with patient clinical outcomes utilising random survival forest (RSF) machine learning. Using material from cohorts of genetically diagnosed Ewing sarcoma with EWSR1 chromosomal translocations, confocal images of tissue microarrays were segmented with level sets and watershed algorithms. Each cell nucleus and cytoplasm were identified in relation to DAPI and CD99, respectively, and protein biomarkers (e.g. Ki67, pS6, Foxo3a, EGR1, MAPK) localised relative to nuclear and cytoplasmic regions of each cell in order to generate image feature distributions. The image distribution features were analysed with RSF in relation to known overall patient survival from three separate cohorts (185 informative cases). Variation in pre-analytical processing resulted in elimination of a high number of non-informative images that had poor DAPI localisation or biomarker preservation (67 cases, 36%). The distribution of image features for biomarkers in the remaining high quality material (118 cases, 104 features per case) were analysed by RSF with feature selection, and performance assessed using internal cross-validation, rather than a separate validation cohort. A prognostic classifier for Ewing sarcoma with low cross-validation error rates (0.36) was comprised of multiple features, including the Ki67 proliferative marker and a sub-population of cells with low cytoplasmic/nuclear ratio of CD99. Through elimination of bias, the evaluation of high-dimensionality biomarker distribution within cell populations of a tumour using random forest analysis in quality controlled tumour material could be achieved. Such an automated and integrated methodology has potential application in the identification of prognostic classifiers based on tumour cell heterogeneity.

Indexed as

12E7 AntigenAlgorithmsAntigens, CDArtificial IntelligenceBiomarkers, TumorBone NeoplasmsCell Adhesion MoleculesCell Line, TumorCell NucleusCytoplasmHumansPrognosisSarcoma, Ewing12E7 AntigenAntigens, CDBiomarkers, TumorCD99 protein, humanCell Adhesion Molecules

Identifiers

PMID25243408
PMCPMC4171480
OpenAlexW1997827764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.